These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38597738)

  • 41. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Lee BP; Dodge JL; Terrault NA
    Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study.
    Oh J; Kim BK; Yoon JH; Lee HH; Park H; Lee J; Park Y; Yun B; Chung J
    Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335133
    [No Abstract]   [Full Text] [Related]  

  • 43. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
    Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
    BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
    Kim D; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1950-1956. PubMed ID: 38740513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: A propensity score-matched analysis.
    Kong G; Cao G; Koh J; Chan SP; Zhang A; Wong E; Chong B; Jauhari SM; Wang JW; Mehta A; Figtree GA; Mamas MA; Ng G; Chan KH; Chai P; Low AF; Lee CH; Yeo TC; Yip J; Foo R; Tan HC; Huang DQ; Muthiah M; Chan MY; Loh PH; Chew NWS
    Diabetes Obes Metab; 2024 Aug; 26(8):3328-3338. PubMed ID: 38779875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
    Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
    Ochoa-Allemant P; Serper M; Wang RX; Tang H; Ghandour B; Khan S; Mahmud N
    Hepatology; 2024 Apr; ():. PubMed ID: 38683569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.
    Chen YT; Chen TI; Yang TH; Yin SC; Lu SN; Liu XR; Gao YZ; Lin CJ; Huang CW; Huang JF; Yeh ML; Huang CF; Dai CY; Chuang WL; Yang HI; Yu ML; Lee MH
    Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38534155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
    Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
    Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population.
    De Vincentis A; Tavaglione F; Namba S; Kanai M; Okada Y; Kamatani Y; Maurotti S; Pedone C; Antonelli Incalzi R; Valenti L; Romeo S; Vespasiani-Gentilucci U
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1402-1412. PubMed ID: 38497224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.
    Chen Q; Hu P; Hou X; Sun Y; Jiao M; Peng L; Dai Z; Yin X; Liu R; Li Y; Zhu C
    Cardiovasc Diabetol; 2024 Jul; 23(1):232. PubMed ID: 38965572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis.
    Mantovani A; Morandin R; Fiorio V; Lando MG; Petta S; Ferraro PM; Targher G
    Intern Emerg Med; 2024 Sep; 19(6):1745-1755. PubMed ID: 38992323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease.
    Roy A; De A; Kulkarni AV; Jajodia S; Goenka U; Tewari A; Sonthalia N; Goenka MK
    J Obes Metab Syndr; 2024 Sep; 33(3):222-228. PubMed ID: 39098054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes.
    Riley DR; Hydes T; Hernadez G; Zhao SS; Alam U; Cuthbertson DJ
    Liver Int; 2024 Oct; 44(10):2538-2550. PubMed ID: 38949295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.